TopFunds

Abbott Laboratories

NYSE: ABT

Stock price

104.88 USD

(+0%) TODAY

Medical - Devices
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
2.9
0.9
0.3
1.3
2.1
2.5
3.9
3.9
3.3
7.6
3.7
2.4%
02Free cash flow per share
1.2
1.4
2.5
2.8
2.5
3.2
4.8
4.4
2.9
3.6
4.2
13.1%
03Dividends per share
1
1
1.1
1.1
1.3
1.4
1.8
1.9
2
2.2
2.4
9.4%
04Dividends payout, %
32.6%
1.1%
3.9%
83.4%
61.6%
57%
45.3%
47.7%
62.1%
28.6%
63.1%
6.8%
PROFIT AND LOSS STATEMENT
05Revenue
20,405
20,853
27,390
30,578
31,904
34,608
43,075
43,653
40,109
41,950
44,328
8.1%
06% Change
-
-
-
-
-
-
-
-
-
-
-
8.1%
07Cost of revenue
(9,445)
(9,609)
(14,324)
(14,755)
(15,211)
(17,231)
(19,861)
(21,330)
(20,072)
(20,625)
(19,721)
7.6%
08Gross profit
10,960
11,244
13,066
15,823
16,693
17,377
23,214
22,323
20,037
21,325
24,607
8.4%
09% Margin
53.7%
53.9%
47.7%
51.8%
52.3%
50.2%
53.9%
51.1%
50%
50.8%
55.5%
51.9% A
10Operating expenses
(8,011)
(7,995)
(11,094)
(11,979)
(12,102)
(12,086)
(14,014)
(13,961)
(13,602)
(14,474)
(16,586)
7.6%
11% of Revenue
(39.3)%
(38.3)%
(40.5)%
(39.2)%
(37.9)%
(34.9)%
(32.5)%
(32)%
(33.9)%
(34.5)%
(37.4)%
(36.4)% A
12Operating Income
2,949
3,249
1,972
3,844
4,591
5,291
9,200
8,362
6,435
6,825
8,048
10.6%
13Income tax expense
(577)
(350)
(1,878)
(539)
(390)
(497)
(1,140)
(1,373)
(941)
(6,389)
(1,942)
12.9%
14Net Income
4,423
1,400
477
2,368
3,687
4,495
7,071
6,933
5,723
13,402
6,524
4%
15% Margin
21.7%
6.7%
1.7%
7.7%
11.6%
13%
16.4%
15.9%
14.3%
32%
14.7%
14.2% A
16Shares Outstanding
1,506
1,483
1,749
1,770
1,781
1,786
1,789
1,764
1,749
1,748
1,747
1.5%
17EPS Basic
3
1
0.3
1.4
2.1
2.5
4
3.9
3.3
7.7
3.7
2.2%
18EPS Diluted
2.9
0.9
0.3
1.3
2.1
2.5
3.9
3.9
3.3
7.6
3.7
2.4%
19EBITDA
4,833
3,070
6,132
6,880
7,909
9,003
12,159
11,888
10,605
10,834
11,923
9.5%
% Margin
23.7%
14.7%
22.4%
22.5%
24.8%
26%
28.2%
27.2%
26.4%
25.8%
26.9%
24.4% A
20Net Interest Income (expense)
(73)
(205)
(756)
(624)
(724)
(662)
(367)
(132)
(313)
(259)
(111)
4.3%
21Net Debt / EBITDA
0.8
1.1
3
2.3
1.9
1.4
0.8
0.7
0.8
0.7
0.5
1.3 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
5,001
18,620
9,407
3,844
3,860
6,838
9,799
9,882
6,896
7,616
8,522
5.5%
23Short-term investments
1,124
155
203
242
280
310
450
288
383
351
417
(9.4)%
24Accounts receivable
3,418
3,248
5,249
5,182
5,425
6,414
6,487
6,218
6,565
6,925
7,929
8.8%
25Other current assets
2,013
2,319
1,687
1,568
1,786
1,867
2,346
2,663
2,256
2,570
2,640
2.8%
26Inventory
2,599
2,434
3,601
3,796
4,316
5,012
5,157
6,173
6,570
6,194
6,488
9.6%
27Total Current Assets
14,155
26,776
20,147
14,632
15,667
20,441
24,239
25,224
22,670
23,656
25,996
6.3%
Non-Current Assets
28Net property, plant & equipment
5,730
5,705
7,607
7,563
8,972
10,130
10,112
10,278
11,276
11,733
12,942
8.5%
29Long-term investments
4,041
2,947
883
897
931
1,031
903
766
799
886
918
(13.8)%
30Other non-current assets
20,075
19,583
47,613
44,081
42,317
40,946
39,942
38,170
38,469
45,139
46,857
8.9%
31Total Non-Current Assets
29,846
28,235
56,103
52,541
52,220
52,107
50,957
49,214
50,544
57,758
60,717
7.4%
Total Assets
44,001
55,011
76,250
67,173
67,887
72,548
75,196
74,438
73,214
81,414
86,713
7%
LIABILITIES
Current Liabilities
32Accounts payable
1,081
1,178
2,402
2,975
3,252
3,946
4,408
4,607
4,295
4,195
4,240
14.6%
33Short-term debt
3,130
1,325
714
207
1,683
461
999
2,481
1,325
1,754
3,309
0.6%
34Other current liabilities
4,975
4,157
5,796
5,830
5,928
7,500
7,698
8,401
8,221
8,208
8,947
6%
35Total Current Liabilities
9,186
6,660
8,912
9,012
10,863
11,907
13,105
15,489
13,841
14,157
16,496
6%
Non-Current Liabilities
36Long-term debt
5,871
20,681
27,210
19,359
17,416
19,429
18,252
15,465
14,548
13,521
11,758
7.2%
37Other non-current liabilities
7,618
6,953
9,030
8,080
8,307
8,209
7,815
6,579
5,998
5,835
5,688
(2.9)%
38Total Non-Current Liabilities
13,489
27,634
36,240
27,439
25,723
27,638
26,067
22,044
20,546
19,356
17,446
2.6%
39Total Liabilities
19,921
31,949
45,152
36,451
36,586
39,545
39,172
37,533
34,387
33,513
33,942
5.5%
SHAREHOLDERS` EQUITY
40Common stock
12,734
13,027
23,206
23,512
23,853
24,145
24,470
24,709
24,869
25,153
25,527
7.2%
41Retained earnings / (deficit)
25,757
25,565
23,978
24,560
25,847
27,627
31,528
35,257
37,554
47,261
49,781
6.8%
42Accumulated other comprehensive income / (loss)
(6,658)
(7,263)
(6,062)
(7,586)
(8,465)
(8,946)
(8,374)
(8,051)
(7,839)
(7,906)
(6,001)
(1)%
43Noncontrolling interests
115
179
201
198
213
219
222
219
224
237
641
18.8%
44Total shareholders' equity
21,326
20,717
31,098
30,722
31,301
33,003
36,024
36,905
38,827
47,901
52,771
9.5%
45Total Liabilities and shareholders' Equity
44,001
55,011
76,250
67,173
67,887
72,548
75,196
74,438
73,214
81,414
86,713
7%
46Total Debt
9,001
22,006
27,924
19,566
19,099
19,890
19,251
17,946
15,873
15,275
15,067
5.3%
47Net Debt
4,000
3,386
18,517
15,722
15,239
13,052
9,452
8,064
8,977
7,659
6,545
5.1%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
4,423
1,400
477
2,368
3,687
4,495
7,071
6,933
5,723
13,402
6,524
4%
49Depreciation & amortization
1,472
1,353
3,021
3,278
3,014
3,327
3,538
3,267
3,243
3,218
3,116
7.8%
50Share-based compensation expense
292
310
406
477
519
546
640
685
644
673
664
8.6%
51Changes in working capital and other assets
(3,221)
140
1,666
177
(1,084)
(467)
(716)
(1,304)
(2,349)
(8,735)
(738)
(13.7)%
52Net cash flows from operating activities
2,966
3,203
5,570
6,300
6,136
7,901
10,533
9,581
7,261
8,558
9,566
12.4%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(1,110)
(1,121)
(1,135)
(1,394)
(1,638)
(2,177)
(1,885)
(1,777)
(2,202)
(2,207)
(2,171)
6.9%
54Purchases of investments / marketable securities
(4,933)
(2,823)
(210)
(131)
(103)
(83)
(173)
(185)
(159)
(169)
(167)
(28.7)%
55Proceeds from maturities of marketable securities
4,112
3,709
129
73
21
10
77
152
43
28
3
(51.4)%
56Other investing activities
2,337
(13)
(8,402)
96
(95)
35
(27)
70
(815)
10
(87)
-
57Net cash flows from investing activities
406
(248)
(9,618)
(1,356)
(1,815)
(2,215)
(2,008)
(1,740)
(3,133)
(2,338)
(2,422)
-
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(2,237)
(522)
(827)
(238)
(718)
(403)
(2,299)
(3,795)
(1,227)
(1,295)
(497)
(14)%
59Dividends paid, net
(1,443)
(1,539)
(1,849)
(1,974)
(2,270)
(2,560)
(3,202)
(3,309)
(3,556)
(3,836)
(4,116)
11.1%
60Debt issuance (repayments), net
1,147
13,155
(1,908)
(8,450)
(1,599)
(50)
(248)
(699)
(2,475)
(537)
(1,614)
-
61Other financing activities
297
53
(697)
271
298
234
255
167
167
264
(82)
-
62Net cash flows from financing activities
(2,236)
11,147
(5,281)
(10,391)
(4,289)
(2,779)
(5,494)
(7,636)
(7,091)
(5,404)
(6,309)
10.9%
63Increase (decrease) in cash and cash equivalents
938
13,619
(9,213)
(5,563)
16
2,978
2,961
83
(2,986)
720
906
(0.4)%
64Cash and equivalents, ending balance
5,001
18,620
9,407
3,844
3,860
6,838
9,799
9,882
6,896
7,616
8,522
5.5%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
1,856
2,082
4,435
4,906
4,498
5,724
8,648
7,804
5,059
6,351
7,395
14.8%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Abbott Laboratories (ABT) financial statements and performance

Explore Abbott Laboratories (ABT) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.